New combo therapy aims to halt spread of aggressive breast cancer
NCT ID NCT06492759
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether adding high-dose radiation to standard immunotherapy (pembrolizumab) and chemotherapy can help control metastatic triple-negative breast cancer that is PD-L1 positive. About 29 participants with at least two sites of metastatic disease will receive the combination. The main goal is to see if this approach improves the time until the cancer progresses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (immunotherapy) plus chemotherapy (paclitaxel, nab-paclitaxel, carboplatin, gemcitabine) and high-dose radiation therapy
What this could lead to
If successful, this combination could improve how long the cancer is kept under control in patients with metastatic triple-negative breast cancer.
What could go wrong
This is a small, early-phase trial with only 29 participants, so results may not apply broadly. The combination of radiation, immunotherapy, and chemotherapy can cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University Hospital/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact